- Home
- MVIS vs TVRD Comparison
MVIS vs TVRD Comparison
Compare MVIS & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVIS
- TVRD
- Stock Information
- Founded
- MVIS 1993
- TVRD 2017
- Country
- MVIS United States
- TVRD United States
- Employees
- MVIS N/A
- TVRD N/A
- Industry
- MVIS Industrial Machinery/Components
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- MVIS Technology
- TVRD Health Care
- Exchange
- MVIS Nasdaq
- TVRD Nasdaq
- Market Cap
- MVIS 287.6M
- TVRD 246.5M
- IPO Year
- MVIS 1996
- TVRD N/A
- Fundamental
- Price
- MVIS $1.12
- TVRD $29.41
- Analyst Decision
- MVIS Buy
- TVRD Strong Buy
- Analyst Count
- MVIS 4
- TVRD 2
- Target Price
- MVIS $2.50
- TVRD $52.00
- AVG Volume (30 Days)
- MVIS 4.8M
- TVRD 48.4K
- Earning Date
- MVIS 05-12-2025
- TVRD 05-13-2025
- Dividend Yield
- MVIS N/A
- TVRD N/A
- EPS Growth
- MVIS N/A
- TVRD N/A
- EPS
- MVIS N/A
- TVRD N/A
- Revenue
- MVIS $4,329,000.00
- TVRD N/A
- Revenue This Year
- MVIS $481.03
- TVRD N/A
- Revenue Next Year
- MVIS $95.03
- TVRD N/A
- P/E Ratio
- MVIS N/A
- TVRD N/A
- Revenue Growth
- MVIS N/A
- TVRD N/A
- 52 Week Low
- MVIS $0.80
- TVRD $8.13
- 52 Week High
- MVIS $1.95
- TVRD $34.31
- Technical
- Relative Strength Index (RSI)
- MVIS 47.51
- TVRD N/A
- Support Level
- MVIS $1.10
- TVRD N/A
- Resistance Level
- MVIS $1.38
- TVRD N/A
- Average True Range (ATR)
- MVIS 0.10
- TVRD 0.00
- MACD
- MVIS 0.01
- TVRD 0.00
- Stochastic Oscillator
- MVIS 30.26
- TVRD 0.00
About MVIS MicroVision Inc.
Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.